PhytoMedical Bolsters Cancer Research Following Favorable ResultsPRINCETON, N.J.--(BUSINESS WIRE)--Feb 4, 2008 - PhytoMedical Technologies, Inc. (OTCBB: PYTO) (FWB: ET6), today announced that favorable research outcomes from ongoing tests have spurred immediate expansion of the Company's cancer research program, actively working to develop patented, next-generation anticancer compounds targeting multiple human cancer strains.
"The results of our ongoing investigation of these patented compounds have been very encouraging, especially when considering that researchers have not only been successful at killing cancer cells from multiple, hard-to-treat cancers, but above all, unlike other studies which simply target cancer cells from animals, these tests have demonstrated our ability to kill cancer cells from humans," explained Mr. Greg Wujek, President and CEO of PhytoMedical Technologies, Inc.
Researchers have recently reported promising results of in vitro studies involving human glioblastoma (brain) and small cell lung cancer cells using bis-acridine compounds. These synthetic bis-acridines have demonstrated significant, favorable activity in killing two difficult-to-treat strains of human cancer cells representative of each of these cancers; DMS-114 small cell lung cancer and SF-295 glioblastoma.
"The promising results of these human cancer cell in-vitro studies have encouraged us to immediately bolster our cancer research initiative," continued Mr. Wujek.
"Through our expanded research program, scientists will undertake new tests of next-generation variations of our patented anticancer compounds. I also look forward to building on our early success against brain and lung cancer cells by targeting other prevalent and difficult-to-treat strains of human cancer, including both breast and colon cancer."
PhytoMedical's Cancer Research: Killing Cancer's DNA
PhytoMedical is developing a novel class of patented anti-cancer agents that have a 'cytotoxic' or poisonous affinity for cancer cells. These new compounds are designed to bind more tightly to cancer cell DNA than many conventional anticancer drugs by a process called bis-intercalation or "double binding," much like a molecular staple. Because the DNA is the blueprint of life for the cancer cell, such binding stops the replication of the DNA, which prevents the growth of the cancer cell and it dies.
DNA is present in the nucleus of every cell of all living organisms, which are constantly dividing through a process in which the DNA in the nucleus of the original cell replicates itself to be present in the nuclei of the two new ("daughter") cells. If this replication cannot occur, the cell will die and the organism will eventually stop growing and die. Cancer is characterized by the development of abnormal cells that divide uncontrollably and have the ability to infiltrate and destroy normal body tissue.
At present, anticancer molecules designed to block the replication of DNA do so through "intercalation," a mechanism in which the drug inserts itself between one set of adjacent base pairs of the DNA. PhytoMedical believes a more effective anticancer strategy is to design molecules ("bis-intercalators") that can intercalate simultaneously at two DNA sites, thus further increasing the binding between the drug and the DNA of specific cancer cells in order to stop their replication and ultimately resulting in the death of the cancer cell.
About PhytoMedical Technologies, Inc.
PhytoMedical Technologies, Inc. (OTCBB: PYTO; Frankfurt Stock Exchange: ET6), together with its wholly owned subsidiaries, is a pharmaceutical company focused on research, development and commercialization of pharmaceutical products.
For additional information, please visit: www.PhytoMedical.com
To receive future press releases via email, please visit:
To view the full HTML text of this release, please visit:
Legal Notice Regarding Forward-Looking Statements
No statement herein should be considered an offer or a solicitation of an offer for the purchase or sale of any securities. This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although the Company believes that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, it can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements, which involve assumptions and describe our future plans, strategies, and expectations, are generally identifiable by use of the words "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to adverse economic conditions, intense competition, lack of meaningful research results, entry of new competitors and products, adverse federal, state and local government regulation, inadequate capital, unexpected costs and operating deficits, increases in general and administrative costs, termination of contracts or agreements, technological obsolescence of the Company's products, technical problems with the Company's research and products, price increases for supplies and components, litigation and administrative proceedings involving the Company, the possible acquisition of new businesses or technologies that result in operating losses or that do not perform as anticipated, unanticipated losses, the possible fluctuation and volatility of the Company's operating results, financial condition and stock price, losses incurred in litigating and settling cases, dilution in the Company's ownership of its business, adverse publicity and news coverage, inability to carry out research, development and commercialization plans, loss or retirement of key executives and research scientists, changes in interest rates, inflationary factors, and other specific risks. We currently have no commercial products intended to diagnose, treat, prevent or cure any disease. The statements contained in this press release regarding our on going research and development and the results attained by us to-date have not been evaluated by the Food and Drug Administration. There can be no assurance that further research and development, and /or whether clinical trial results, if any, will validate and support the results of our preliminary research and studies. Further, there can be no assurance that the necessary regulatory approvals will be obtained or that PhytoMedical will be able to develop commercially viable products on the basis of its technologies. In addition, other factors that could cause actual results to differ materially are discussed in the Company's most recent Form 10-QSB and Form 10-KSB filings with the Securities and Exchange Commission. These reports and filings may be inspected and copied at the Public Reference Room maintained by the U.S. Securities & Exchange Commission at 100 F Street, N.E., Washington, D.C. 20549. You can obtain information about operation of the Public Reference Room by calling the U.S. Securities & Exchange Commission at 1-800-SEC-0330. The U.S. Securities & Exchange Commission also maintains an Internet site that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the U.S. Securities & Exchange Commission at http://www.sec.gov. The Company undertakes no obligation to publicly release the results of any revisions to these forward looking statements that may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
PhytoMedical Technologies, Inc.
Mr. Greg Wujek, 800-611-3388
President & CEO
Posted: February 2008